A new study from University of Wurzburg in Germany has found vital clues that may lead to development of new treatments for aggressive childhood cancer.
Previous studies have shown that amplification of the MYCN gene, which disrupts control of cell division and differentiation, is a strong predictor of poor prognosis in neuroblastoma, the most common cancer in young children.
Treatment of Neuroblastoma in Near Future?
Researchers in Australia have identified a potential new target for treatment of neuroblastoma, the most common solid tumour among young children.
Researchers in Australia have identified a potential new target for treatment of neuroblastoma, the most common solid tumour among young children.
During the study, the research team led by Eilers analysed almost 200 genes that interact with MYCN.
They found a gene called AURKA responsible for the growth of deadly MYCN-amplified neuroblastoma cells.
AURKA encodes the enzyme Aurora A, which is dysregulated in cancer cells like neuroblastoma cells.
"Our results show that stabilization of N-Myc is a critical oncogenic function of Aurora A in childhood neuroblastoma; the challenge will now be to find ways to interfere with this function in order to find new approaches for the therapy of these tumours," said Eilers.
Advertisement
Novel Approach can Strengthen Immune System Against Childhood Cancer
A team of researchers from Baylor College of Medicine and Texas Children's Hospital has found that the ability of the immune system cells called T-lymphocytes to fight childhood cancer.
A team of researchers from Baylor College of Medicine and Texas Children's Hospital has found that the ability of the immune system cells called T-lymphocytes to fight childhood cancer.
Source-ANI
PRI/SK
Gene That Causes Childhood Nerve Cancer Identified
Researchers have identified the hereditary gene mutations behind a deadly form of childhood cancer, opening the way to genetic tests in high-risk families, according to study released Sunday.
Researchers have identified the hereditary gene mutations behind a deadly form of childhood cancer, opening the way to genetic tests in high-risk families, according to study released Sunday.
